Physician profile
Amy Francis
NPI 1679235915
$5,752.23
in general payments reported to CMS, 2019-2025
33 companies · $4,120 in 2025
The $4,120 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.41 · 2022: $428 · 2023: $467 · 2024: $720 · 2025: $4,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,241 · Education: $66.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,240.59 |
| Education | $66.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,059.15 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $612.11 | 2025 | Andembry, Hizentra, Haegarda |
| Genzyme Corporation | $576.52 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $543.20 | 2025 | Cuvitru, Eohilia, Hyqvia |
| Glaxosmithkline, LLC. | $364.51 | 2022-2025 | Bexsero, Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $322.32 | 2025 | Dupixent |
| Ionis Pharmaceuticals, INC. | $241.31 | 2025 | Dawnzera |
| Pfizer INC. | $216.84 | 2022-2025 | |
| Biocryst US Sales Co., LLC | $209.05 | 2025 | Orladeyo |
| Merck Sharp & Dohme LLC | $192.66 | 2022-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Sanofi Pasteur INC. | $187.54 | 2022-2025 | |
| Cumberland Pharmaceuticals, INC. | $176.87 | 2022-2023 | Kristalose |
| Incyte Corporation | $140.13 | 2025 | Opzelura |
| Cranial Technologies, INC | $126.19 | 2022-2024 | Doc Band |
| Grifols USA, LLC | $80.85 | 2025 | Xembify |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $67.42 | 2025 | |
| Amgen INC. | $66.16 | 2025 | Tezspire |
| Phadia US INC. | $57.56 | 2023-2025 | Immunocap |
| Verona Pharma, INC. | $55.06 | 2025 | Ohtuvayre |
| Corium, LLC | $50.75 | 2022 | |
| Seqirus USA INC | $49.21 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Sanofi-Aventis U.S. LLC | $43.86 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $40.53 | 2022-2024 | Crysvita |
| Hikma Pharmaceuticals USA | $39.23 | 2023-2025 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $33.01 | 2025 | Neffy |
| Genentech USA, INC. | $31.84 | 2025 | Xolair |
| Paratek Pharmaceuticals, INC. | $29.78 | 2025 | Xhance |
| Verrica Pharmaceuticals INC. | $27.43 | 2024 | Ycanth |
| Alk-Abello, INC | $24.65 | 2024 | Grastek, Ragwitek, Odactra |
| Abbvie INC. | $24.37 | 2022 | |
| Galderma Laboratories, L.P. | $23.24 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $21.47 | 2025 | Sajazir |
| Aytu Biopharma, INC. | $17.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.